We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




New Blood Draw Device Evaluated For Hemolysis

By LabMedica International staff writers
Posted on 06 Feb 2018
Print article
Image: A blood draw using the PIVO device which allows patients to have blood taken multiple times during their hospital stay without having to undergo multiple needle sticks (Photo courtesy of Intermountain Healthcare).
Image: A blood draw using the PIVO device which allows patients to have blood taken multiple times during their hospital stay without having to undergo multiple needle sticks (Photo courtesy of Intermountain Healthcare).
Hemolysis, defined as the breakdown of red blood cells and the release of hemoglobin and intracellular contents into the plasma, is a frequent occurrence in blood samples submitted to clinical laboratories for testing.
 
Blood collections from peripheral intravenous catheters offer several benefits to patients, including reduced needle punctures and patient discomfort, but they risk reducing the quality of blood specimens analyzed by the laboratory. The estimated prevalence of hemolyzed specimens is approximately 3% of routine samples and they make up approximately 60% of specimens classified as unsuitable for analysis.
 
A team of medical laboratory scientists led by those at University Hospitals Cleveland Medical Center (Cleveland, OH, USA), in an effort to balance analytical quality of test results with patient-centered care initiatives, a needle-less blood collection device called PIVO (Velano Vascular, San Francisco, CA, USA) was evaluated at two institutions. The primary objective of this study was to assess the ability of the PIVO device to provide high-quality blood specimens for laboratory testing compared to current blood collection methods.
 
The PIVO blood collection device was used for blood draws from a peripheral intravenous (IV) catheter (PIVC). Prior to the PIVO collection, the IV catheter was flushed with 5 mL normal saline. The PIVO device was attached to the needle-less valve and actuated through the IV catheter into the blood stream. Standard vacuum tubes or a syringe were used at the back end of the device to collect blood samples. The blood collections were typically performed with a tourniquet above the PIVC. A discard volume of 1 mL was collected through PIVO prior to the required specimen collection. After the PIVO collection the device was retracted, removed, and disposed of. The IV catheter was again flushed with 5 mL normal saline.
 
Specimen integrity was checked by the semi-quantitative, spectrophotometric assessment of hemolysis in human serum and plasma on automated chemistry analyzers. Hemolysis flags were appended to test results when the hemolysis index corresponding to a free hemoglobin concentration of ≥ 50 mg/dL was triggered for blood chemistry test samples requiring an automated specimen integrity check. Approximately 7,600 PIVO blood draws were performed across the two institutions. The hemolysis rates of samples collected with PIVO were evaluated using 2,380 flagged collections, containing approximately 1,200 test orders requiring hemolysis index measurements. The hemolysis rate of PIVO-flagged samples (1.8%) was statistically superior to the venipuncture and central line blood collection methods (3.3%), reducing the risk of hemolysis during a venous blood draw by 39%.
 
The authors concluded that PIVO collections facilitated improvement in the rate and degree of sample hemolysis when compared to venipuncture and central line blood collections. These findings suggest that PIVO is capable of delivering samples that are superior to current blood collection methods in terms of hemolysis rate as well as reducing the number of invasive venipunctures required for laboratory testing. The study was published on January 4, 2018, in the journal Practical Laboratory Medicine.
 
Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Herpes Simplex Virus ELISA
HSV 2 IgG – ELISA
New
Silver Member
Fixed Speed Tube Rocker
GTR-FS

Print article

Channels

Clinical Chemistry

view channel
Image: Professor Nicole Strittmatter (left) and first author Wei Chen stand in front of the mass spectrometer with a tissue sample (Photo courtesy of Robert Reich/TUM)

Mass Spectrometry Detects Bacteria Without Time-Consuming Isolation and Multiplication

Speed and accuracy are essential when diagnosing diseases. Traditionally, diagnosing bacterial infections involves the labor-intensive process of isolating pathogens and cultivating bacterial cultures,... Read more

Molecular Diagnostics

view channel
Image: Health Canada has approved SPINEstat, a first-in-class diagnostic blood test for axSpA, as a Class II medical device (Photo courtesy of Augurex)

First-in-Class Diagnostic Blood Test Detects Axial Spondyloarthritis

Axial spondyloarthritis (axSpA) is a chronic inflammatory autoimmune condition that typically affects individuals during their most productive years, with symptoms often emerging before the age of 45.... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.